Dasatinib plus quercetin combination tested in open-label pilot for aging markers in depression or schizophrenia.
This pilot open-label study examined dasatinib plus quercetin, a combination selected for senolytic properties, in older individuals with depression or schizophrenia. The study assessed effects on physiological aging markers. No results, effect sizes, or sample size details were reported in the abstract.
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Apr 21, 2026 · Discovered: Sep 16, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Other
- Sample size
- —
- Duration
- —
- Population
- —
- Primary outcome
- —
- Effect size
- —
- Significance
- Not reported
- Journal
- Washington University School of Medicine
- Published
- Apr 21, 2026
Sources
Primary source
- Washington University School of Medicine ↗Clinical trial
Source versions
Assessment history
9/23/2026 · SUPERSEDED: Source updated; assessment withdrawn pending review.
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
No comments yet
Be the first to weigh in on this evidence.